Sort
21,453 grants matching “tuberculosis”
Human immune signatures of latent MTB infection, active disease and BCG vaccination
$950,551Bjoern Peters · La Jolla Institute For Immunology · U19 · FY2019 · AI
Task A12 Small Animal Models for Testing of Products Against Mycobacteria
$950,318 · N01 · FY2010 · AI
Human Dendritic Cell Subsets
$950,220Jacques F Banchereau · Baylor Research Institute · U19 · FY2008 · AI
Targeted vaccines against pulmonary NTM infections in vulnerable populations
$950,092Rhea N Coler · Seattle Children'S Hospital · R01 · FY2025 · AI
Development of Aersolized Vaccines
$949,976Mario Roederer · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
Immunoregulation /Immune Recognition In Filarial/Nonfilarial Parasitic Infection
$949,793Thomas Nutman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Exploration, conservation, & development of marine biodiversity in Fiji and the S
$948,534Mark E Hay · Georgia Institute Of Technology · U19 · FY2018 · TW
Rapid DPP test for tuberculosis
$948,385Konstantin P Lyashchenko · Chembio Diagnostic Systems, Inc. · R44 · FY2011 · AI
Novel Stem Cell Immunotherapy for MDR-Tuberculosis
$948,345Chinnaswamy Jagannath · Methodist Hospital Research Institute · R01 · FY2025 · AI
International Clinical Trials Unit
$948,184John A Bartlett · Duke University · U01 · FY2007 · AI
Bacterial disruption of neuroimmune pathways in a transparent brain
$948,000Cressida Arianna Madigan · University Of California, San Diego · DP2 · FY2024 · NS
Viable but Nonculturable Mtb
$947,618Carl F Nathan · Weill Medical Coll Of Cornell Univ · U19 · FY2020 · AI
Innate, Transcriptomic, and Microbiomic correlates of TB infection
$946,851Michael Haggai Glickman · Weill Medical Coll Of Cornell Univ · U19 · FY2017 · AI
Novel therapeutic agent to prevent hearing loss during aminoglycoside therapy
$946,196Malcolm Gleser · Oricula Therapeutics, Llc · R44 · FY2016 · AI
Influence of SIV replication on TB progression and immunity
$945,816Zandrea Ambrose · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · AI
Improving specificity of HPV Screen-and-Treat in South Africa
$945,771Louise Kuhn · Columbia University Health Sciences · UH3 · FY2018 · CA
Closing the Gaps on Buruli Ulcer Diagnosis, Treatment, and Prevention
$945,739Eric L Nuermberger · Johns Hopkins University · R01 · FY2016 · AI
TUBERCULOSIS CONTROL PROGRAM AND AIDS
$945,386Md, Robert L. Brawley · Cabinet For Health And Family Services · U52 · FY2007 · PS
Development of novel proteins synthesis inhibitors for MDR tuberculosis
$945,212Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2012 · AI
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)
$944,359Michael David Hughes · Harvard School Of Public Health · UM1 · FY2022 · AI
Fox COBRE Phase II Admin Core
$944,312Joseph M Fox · University Of Delaware · P20 · FY2023 · GM
Lead Optimization and Preclinical Development of a small molecule inhibitor of M. avium KasA
$944,067David Alland · Hackensack University Medical Center · U19 · FY2025 · AI
Large Scale T Cell Epitope Discovery: Proteome-wide characterization of T cell epitopes from Mycobacterium tuberculosis in vaccination and active infection
$943,977Bjoern Peters · La Jolla Institute For Immunology · N01 · FY2023 · AI
LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the US
$942,554Sharon A Nachman · Johns Hopkins University · UM1 · FY2020 · AI
DISSEMINATED TUBERCULOSIS IN HIV INFECTION
$942,272Dartmouth College · R01 · FY2003 · AI